Evidence map›Paper›PMID 31048544›Full record

ArticleGenes & development2019

ATDC is required for the initiation of KRAS-induced pancreatic tumorigenesis.

Lidong Wang, Huibin Yang, Andrea Zamperone, Daniel Diolaiti, Phillip L Palmbos, Ethan V Abel, Vinee Purohit, Igor Dolgalev, Andrew D Rhim, Mats Ljungman and 6 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & development, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. The pancreatic cancer genome revisited.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Lidong WangDepartment of Surgery, New York University School of Medicine, New York, New York 10016, USA.
Huibin YangDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA.
Andrea ZamperoneDepartment of Surgery, New York University School of Medicine, New York, New York 10016, USA.
Daniel DiolaitiDepartment of Surgery, New York University School of Medicine, New York, New York 10016, USA.
Phillip L PalmbosDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.
Ethan V AbelDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, USA.
Vinee PurohitDepartment of Surgery, New York University School of Medicine, New York, New York 10016, USA.
Igor DolgalevPerlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, New York 10016, USA.
Andrew D RhimDepartment of Gastroenterology, Hepatology, and Nutrition, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Mats LjungmanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan 48109, USA.
Christina H HadjuDepartment of Pathology, New York University School of Medicine, New York, New York 10016, USA.
Christopher J HalbrookDepartment of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, USA.
Dafna Bar-SagiPerlmutter Cancer Center, NYU Langone Medical Center, New York University, New York, New York 10016, USA.
Marina Pasca di MaglianoDepartment of Surgery, University of Michigan, Ann Arbor, Michigan 48109, USA.
Howard C CrawfordDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA.
Diane M SimeoneDepartment of Surgery, New York University School of Medicine, New York, New York 10016, USA.
University of Michigan–Ann Arbor · USNew York University · USNYU Langone Health · USThe University of Texas MD Anderson Cancer Center · US

Funding

Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2013 to 2023
$13.5M
Early Detection Biomarkers in Pancreatic AdenocarcinomaR01CA131045 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SIMEONE, DIANE M · 2008 to 2019
$3.2M
Oncogenic Function of ATDC in Bladder CancerR01CA174836 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SIMEONE, DIANE M · 2014 to 2018
$2.3M
Role of Neurogenic Inflammation in Pancreatic CancerR01CA177857 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DAVIS, BRIAN M · 2013 to 2017
$2.1M
NCI NIH HHS P01 CA165980NCI NIH HHS R01 CA131045NCI NIH HHS R01 CA174836NCI NIH HHS R01 CA177857
6 · The paper itself

Abstract

Pancreatic adenocarcinoma (PDA) is an aggressive disease driven by oncogenic KRAS and characterized by late diagnosis and therapeutic resistance. Here we show that deletion of the ataxia-telangiectasia group D-complementing (

Indexed as

CarcinogenesisAcinar CellsAnimalsbeta CateninCarcinoma in SituCarcinoma, Pancreatic DuctalCells, CulturedCell TransdifferentiationDNA-Binding ProteinsDown-RegulationGene Knockdown TechniquesHumansMetaplasiaMiceMice, TransgenicPancreatic Ductsbeta CateninCTNNB1 protein, humanCTNNB1 protein, mouseDNA-Binding ProteinsHras protein, mouseProto-Oncogene Proteins p21(ras)SOX9 protein, humanSox9 protein, mouseSOX9 Transcription FactorTranscription FactorsTRIM29 protein, humanTRIM29 protein, mouseacinar-to-ductal metaplasiaATDCKRASpancreatic ductal adenocarcinomaPanIN lesionSOX9TRIM29β-catenin

Identifiers

PMID31048544
PMCPMC6546061
OpenAlexW2943146530

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.